These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2921366)

  • 21. Eicosanoid synthesis in duodenal ulcer disease: decrease in leukotriene C4 by colloidal bismuth subcitrate.
    Ahmed A; Salmon PR; Cairns CR; Hobsley M; Hoult JR
    Gut; 1992 Feb; 33(2):159-63. PubMed ID: 1541409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipolytic activity of Campylobacter pylori: effect of colloidal bismuth subcitrate (De-Nol).
    Slomiany BL; Kasinathan C; Slomiany A
    Am J Gastroenterol; 1989 Oct; 84(10):1273-7. PubMed ID: 2801678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Campylobacter pylori and trials of ulcer recurrence.
    Chiverton SG; Veuldhuyzen van Zanten SJ; Hunt RH
    J Clin Gastroenterol; 1989 Apr; 11(2):237. PubMed ID: 2738364
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of Campylobacter pylori gastritis: a pilot study using pirenzepine dihydrochloride (Gastrozepin) and three formulations of colloidal bismuth subcitrate (De-Nol).
    Morris A; Brown P; Ali MR; Lane M; Palmer R
    N Z Med J; 1988 Oct; 101(856 Pt 1):651-4. PubMed ID: 3054641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of nizatidine, clarithromycin and bismuth subcitrate therapy for Helicobacter pylori eradication in duodenal ulcer patients--a preliminary report.
    Papp J; Juhasz L; Lakatos L; Lonovits J; Szekely I; Tarnok F; Tulassay Z; Varkonyi T
    Br J Clin Pract; 1996; 50(5):249-53. PubMed ID: 8794601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duodenal ulcer relapse after eradication of Campylobacter pylori.
    Marshall BJ; Warren JR; Goodwin CS
    Lancet; 1989 Apr; 1(8642):836-7. PubMed ID: 2564914
    [No Abstract]   [Full Text] [Related]  

  • 27. Duodenal ulcer relapse after eradication of Campylobacter pylori.
    Lam SK
    Lancet; 1989 Feb; 1(8634):384. PubMed ID: 2563535
    [No Abstract]   [Full Text] [Related]  

  • 28. The role of colloidal bismuth subcitrate in gastric ulcer and gastritis.
    Tytgat GN; Rauws E; Langenberg W
    Scand J Gastroenterol Suppl; 1986; 122():22-9. PubMed ID: 3535018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colloidal bismuth subcitrate.
    Simjee AE
    S Afr Med J; 1988 Jul; 74 Suppl():61-3. PubMed ID: 3291158
    [No Abstract]   [Full Text] [Related]  

  • 30. [What is safe in the treatment of Campylobacter pylori-induced gastritis and Campylobacter pylori-associated peptic ulcer?].
    Menge H
    Internist (Berl); 1988 Nov; 29(11):745-54. PubMed ID: 3069787
    [No Abstract]   [Full Text] [Related]  

  • 31. A comparison of colloidal bismuth subcitrate tablets and ranitidine in the treatment of chronic duodenal ulcers.
    Ward M; Halliday C; Cowen AE
    Digestion; 1986; 34(3):173-7. PubMed ID: 3530861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro synergistic activity between bismuth subcitrate and various antimicrobial agents against Campylobacter pyloridis (C. pylori).
    Van Caekenberghe DL; Breyssens J
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1429-30. PubMed ID: 3674850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synergism between clindamycin and colloidal bismuth subcitrate against Helicobacter (Campylobacter) pylori in vitro.
    Vogt K; Hahn H
    Zentralbl Bakteriol; 1990 Nov; 274(2):246-9. PubMed ID: 2085373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial.
    Humphreys H; Bourke S; Dooley C; McKenna D; Power B; Keane CT; Sweeney EC; O'Moráin C
    Gut; 1988 Mar; 29(3):279-83. PubMed ID: 3356357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of bismuth-containing compounds.
    Lambert JR
    Rev Infect Dis; 1991; 13 Suppl 8():S691-5. PubMed ID: 1925310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia.
    Vaira D; Holton J; Ainley C; Falzon M; Osborn J; D'Anna L; Romanos A; Chandrakumaran K; McNeil I
    Ital J Gastroenterol; 1992 Sep; 24(7):400-4. PubMed ID: 1392023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colloidal bismuth subcitrate in non-ulcer dyspepsia.
    Khanna MU; Abraham P; Nair NG; Mistry FP; Vora IM
    J Postgrad Med; 1992; 38(3):106-8. PubMed ID: 1303406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate.
    Loffeld RJ; Potters HV; Stobberingh E; Flendrig JA; van Spreeuwel JP; Arends JW
    Gut; 1989 Sep; 30(9):1206-12. PubMed ID: 2680795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological gastritis in duodenal ulcer: relationship to Campylobacter pylori and effect of ulcer therapy.
    Dooley CP; McKenna D; Humphreys H; Bourke S; Keane CT; Sweeney E; O'Morain C
    Am J Gastroenterol; 1988 Mar; 83(3):278-82. PubMed ID: 3344730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A consensus on some problems of Helicobacter pylori (draft)].
    Zhonghua Nei Ke Za Zhi; 1997 Jul; 36(7):438-9. PubMed ID: 10436941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.